Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

481480

Sigma-Aldrich

NF-κB SN50

≥97% (HPLC), lyophilized, NF-κB translocation inhibitor, Calbiochem®

Sinonimo/i:

NF-κB SN50, Cell-Permeable Inhibitor Peptide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

500 μG
CHF 260.00
1 MG
CHF 391.00

CHF 260.00


Spedizione prevista il06 aprile 2025


Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
500 μG
CHF 260.00
1 MG
CHF 391.00

About This Item

Formula empirica (notazione di Hill):
C129H230N36O29S
Peso molecolare:
2781.50
Codice UNSPSC:
12352200
NACRES:
NA.77

CHF 260.00


Spedizione prevista il06 aprile 2025


Richiedi un ordine bulk

Nome del prodotto

NF-κB SN50, Cell-Permeable Inhibitor Peptide, NF-κB SN50, CAS 213546-43-3, is a cell-permeable peptide that contains the NLS sequence of NF-κB p50 linked to the hydrophobic region of K-FGF. Inhibits translocation of the NF-κB into the nucleus.

Livello qualitativo

Saggio

≥97% (HPLC)

Stato

lyophilized

Produttore/marchio commerciale

Calbiochem®

Condizioni di stoccaggio

OK to freeze
desiccated (hygroscopic)

Solubilità

water: 5 mg/mL

Condizioni di spedizione

ambient

Temperatura di conservazione

−20°C

Descrizione generale

Contains the nuclear localization sequence (NLS) of the transcription factor NF-κB p50 linked to the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). The N-terminal K-FGF h-region confers cell-permeability, while the NLS (360-369) inhibits translocation of the NF-κB active complex into the nucleus. In murine endothelial LE-II cells induced by LPS, NF-κB nuclear translocation is maximally inhibited at 18 µM.
Contains the nuclear localization sequence (NLS) of the transcription factor NF-κB p50 linked to the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). The peptide N-terminal K-FGF h-region confers cell-permeability, while the NLS (360-369) inhibits translocation of the NF-κB active complex into the nucleus. In murine endothelial LE-II cells induced by LPS, inhibition of NF-κB nuclear translocation is maximally inhibited at 18 µM.
NF-κB SN50, CAS 213546-43-3, is a cell-permeable peptide that contains the NLS sequence of NF-κB p50 linked to the hydrophobic region of K-FGF. Inhibits translocation of the NF-κB into the nucleus.

Azioni biochim/fisiol

Cell permeable: yes
Primary Target
translocation of the NF-κB active complex into the nucleus
Product does not compete with ATP.

Attenzione

Toxicity: Standard Handling (A)

Sequenza

H-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH

Stato fisico

Supplied as a trifluoroacetate salt.

Ricostituzione

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Avoid freeze/thaw cycles of solutions.

Altre note

Lin, Y.-Z., et al. 1995. J. Biol. Chem. 270, 14255.

Note legali

Sold under license of U.S. Patents 5,807,746 and 6,043,339 for research use only. Licenses for commercial manufacture, commercial use, diagnostics, or therapeutics may be obtained by contacting Vanderbilt University, Nashville, Tennessee.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Johanna R Reed et al.
PloS one, 7(9), e45877-e45877 (2012-10-03)
Tumor formation is an extensive process requiring complex interactions that involve both tumor cell-intrinsic pathways and soluble mediators within the microenvironment. Tumor cells exploit the intrinsic functions of many soluble molecules, including chemokines and their receptors, to regulate pro-tumorigenic phenotypes
Taewoo Yang et al.
Journal of experimental & clinical cancer research : CR, 41(1), 82-82 (2022-03-05)
BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistance remain unclear. In silico bioinformatic analysis was performed to identify the most active transcription factor

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.